SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2019-04, Vol.185 (1), p.145-147
Hauptverfasser:	Shi, John, Bodo, Juraj, Zhao, Xiaoxian, Durkin, Lisa, Goyal, Tanu, Meyerson, Howard, Hsi, Eric D.
Format:	Artikel
Sprache:	eng
Schlagworte:	antibody therapy Biomarkers Biomarkers, Tumor diagnostic haematology Hematology Humans Immunohistochemistry Immunophenotyping Lymphoma lymphomas Molecular Targeted Therapy Phenotype Plasmablastic Lymphoma - diagnosis Plasmablastic Lymphoma - drug therapy Plasmablastic Lymphoma - genetics Plasmablastic Lymphoma - metabolism Prognosis Signaling Lymphocytic Activation Molecule Family - genetics Signaling Lymphocytic Activation Molecule Family - metabolism Therapeutic applications
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!